ARG, with offices in Charlottesville, London, Amsterdam, Steinhausen, Warsaw, and Sydney, is supporting its locations and therapeutic expertise with 2022 and 2023 travel plans.
Senior Vice President of Business Development Mike Baker: “We are happy to be getting back on the road to tell our story and listen to the needs of potential sponsors. In December of 2019–right before the pandemic–we traveled to Australia for a conference for the Motor Neuron Disease Association (MNDA). After that things understandably slowed down for quite some time.”
In 2022, ARG has already traveled to New Orleans for The American Association of Cancer Research (AACR) Annual Meeting. Represented by Corina Gastelum Moorehead (Project Manager) and Carmel Nail (Clinical Team Lead), ARG has a profound interest in oncology clinical research projects. In June, Mike Baker will head to Chicago for the American Society of Clinical Oncology (ASCO) Annual Meeting.
Also coming up, ARG will attend major neurology clinical research events. ARG is committed to neurodegenerative disease clinical research, and part of the tight-knit ALS community. CEO Paul Bishop and Senior Vice President of Business Development Mike Baker will be in Boston May 24-26 for the ALS Drug Development Summit. In addition, Dr. Ignazio Di Giovanna, Vice President, Scientific Affairs, Neurology, will be attending the annual ENCALS meeting 2022 in Edinburgh, Scotland June 1-3.
ARG has additional plans to travel to Western Europe later this summer, not only to reinforce our existing locations but to support a new entity in Germany. The trip, a trade mission led by the Virginia Economic Development Partnership (VEDP) will take place between September 12 and 16. Finally, again in association with the VEDP, ARG will participate in another trade mission, this one to the United Kingdom in May of 2023.
Please read more about our complete suite of global service solutions, including Decentralized Clinical Trials (DCTs), retrospective studies and rescue studies on the ARG Services Page.